FDA grants orphan designation to TiGenix ’s Cx601 for Crohn’s disease

The US Food and Drug Administration (FDA) has granted orphan drug designation to Belgian biopharmaceutical firm TiGenix ’s Cx601 to treat patients with fistulizing Crohn’s disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news